[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
…, N Piaraksa, P Hanboonkunupakarn… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …
antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - ELife, 2023 - elifesciences.org
Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
…, EM Batty, P Hanboonkunupakarn… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
[HTML][HTML] Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis …
…, P Khanthagan, B Hanboonkunupakarn… - The Lancet Infectious …, 2024 - thelancet.com
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - medRxiv, 2022 - medrxiv.org
Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - medRxiv, 2022 - medrxiv.org
Background There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
[HTML][HTML] Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized …
…, T Roongrawee, P Hanboonkunupakarn… - OBM Integrative and …, 2024 - lidsen.com
Reports indicate that Andrographolide inhibits viral replication and reduces COVID-19
symptoms. This study aimed to determine Andrographolide's additional effect and safety in mild …
symptoms. This study aimed to determine Andrographolide's additional effect and safety in mild …
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants (preprint)
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - 2022 - pesquisa.bvsalud.org
BackgroundUncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
Pharmacometric assessment of the in-vivo antiviral activity of ivermectin in early symptomatic COVID-19 (preprint)
…, P Hanboonkunupakarn, B Hanboonkunupakarn… - 2022 - pesquisa.bvsalud.org
Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
